Trasylol Lawsuit

Patients and families around the United States are filing Trasylol lawsuits based on the side effects of the drug. Currently no Trasylol class action suits have been filed and claims are being filed individually. The lawsuits claim that the drug’s manufacturer, Bayer, was negligent in several different ways including:

• marketing and selling Trasylol as a safe and effective medication for heart surgery patients
• failing to adequately warn patients of unreasonable and dangerous side effects some of which are fatal
• failing to conduct adequate pre-clinical testing and post-marketing studies to determine the safety and side effects of Trasylol
• failing to use ordinary care in designing, testing and manufacturing Trasylol

In addition, the suits have included counts alleging strict liability, fraud, misrepresentation, deceptive trade practices and breach of express and implied warranties. Trasylol (also referred to as Aprotinin) is a naturally occurring enzyme inhibitor obtained from bovine lung. Trasyol was approved by the FDA in 1993 to help reduce bleeding in heart surgery patients. Since its approval, Trasylol has been given to an estimated 4.3 million patients.

In 2006 the serious problems with Trasyol were highlighted in the first of what has been an increasing number of studies. On January 26, 2006, The New England Journal of Medicine (NEJM) published an article that associated Trasylol with potentially fatal side effects including kidney failure. Following increasing evidence of the drug’s serious side effects, Trasylol was finally removed from the marketplace on November 5, 2007.

A Trasylol lawsuit is a civil legal claim filed on behalf of patients who have suffered side effects or died following use of the drug. Trasylol claims are filed against Bayer A.G., a German corporation, and its subsidiaries Bayer Corporation and Bayer Healthcare. A Trasylol class action lawsuit is filed on behalf of a group of individuals who have suffered side effects and are represented in the same case.